{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:59:25Z","timestamp":1790834365354,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,6,2]],"date-time":"2018-06-02T00:00:00Z","timestamp":1527897600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,6,2]],"date-time":"2018-06-02T00:00:00Z","timestamp":1527897600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000884","name":"Cancer Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000884","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s00345-018-2359-7","type":"journal-article","created":{"date-parts":[[2018,6,2]],"date-time":"2018-06-02T15:17:01Z","timestamp":1527952621000},"page":"1741-1748","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Immune phenotype of peripheral blood mononuclear cells in patients with high-risk non-muscle invasive bladder cancer"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5722-2075","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Audenet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam M.","family":"Farkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Anastos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Galsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Bhardwaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Sfakianos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,2]]},"reference":[{"issue":"1","key":"2359_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67(1):7\u201330","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"2359_CR2","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.juro.2017.04.086","volume":"198","author":"SS Chang","year":"2017","unstructured":"Chang SS, Bochner BH, Chou R, Dreicer R, Kamat AM, Lerner SP et al (2017) Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/ASTRO\/SUO guideline. J Urol sept 198(3):552\u2013559","journal-title":"J Urol sept"},{"issue":"3","key":"2359_CR3","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","volume":"71","author":"M Babjuk","year":"2017","unstructured":"Babjuk M, B\u00f6hle A, Burger M, Capoun O, Cohen D, Comp\u00e9rat EM et al (2017) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol mars 71(3):447\u2013461","journal-title":"Eur Urol mars"},{"issue":"11","key":"2359_CR4","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s40273-014-0194-2","volume":"32","author":"C Yeung","year":"2014","unstructured":"Yeung C, Dinh T, Lee J (2014) The health economics of bladder cancer: an updated review of the published literature. PharmacoEconomics 32(11):1093\u20131104","journal-title":"PharmacoEconomics"},{"issue":"6165","key":"2359_CR5","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1126\/science.342.6165.1432","volume":"342","author":"J Couzin-Frankel","year":"2013","unstructured":"Couzin-Frankel J (2013) Breakthrough of the year 2013. Cancer immunotherapy. Science 342(6165):1432\u20131433","journal-title":"Science"},{"issue":"3","key":"2359_CR6","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrurol.2014.15","volume":"11","author":"G Redelman-Sidi","year":"2014","unstructured":"Redelman-Sidi G, Glickman MS, Bochner BH (2014) The mechanism of action of BCG therapy for bladder cancer\u2014a current perspective. Nat Rev Urol mars 11(3):153\u2013162","journal-title":"Nat Rev Urol mars"},{"key":"2359_CR7","volume-title":"TNM classification of malignant tumours","author":"J Brierley","year":"2017","unstructured":"Brierley J, Gospodarowicz MK, Wittekind C (2017) TNM classification of malignant tumours, 8th edn. John Wiley & Sons Inc., Chichester, Hoboken","edition":"8"},{"key":"2359_CR8","first-page":"359","volume-title":"Pathology and genetics of tumours of the urinary system and male genital organs","author":"JN Eble","year":"2004","unstructured":"Eble JN, Sauter G, Epstein JI, Sesterhenn IA (2004) Pathology and genetics of tumours of the urinary system and male genital organs. IARC Press, Lyon, p 359 (World Health Organization classification of tumours)"},{"key":"2359_CR9","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/00000441-189305000-00001","volume":"105","author":"WB Coley","year":"1893","unstructured":"Coley WB (1893) The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. Am J Med Sci 105:487\u2013511","journal-title":"Am J Med Sci"},{"issue":"1","key":"2359_CR10","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S0022-5347(17)55282-9","volume":"124","author":"DL Lamm","year":"1980","unstructured":"Lamm DL, Thor DE, Harris SC, Reyna JA, Stogdill VD, Radwin HM (1980) Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J Urol juill 124(1):38\u201340","journal-title":"J Urol juill"},{"issue":"5","key":"2359_CR11","doi-asserted-by":"publisher","first-page":"e755","DOI":"10.1016\/j.clgc.2017.03.007","volume":"15","author":"D D\u2019Andrea","year":"2017","unstructured":"D\u2019Andrea D, Moschini M, Gust K, Abufaraj M, \u00d6zsoy M, Mathieu R et al (2017) prognostic role of neutrophil-to-lymphocyte ratio in primary non-muscle-invasive bladder cancer. Clin Genitourin Cancer 15(5):e755\u2013e764","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"2359_CR12","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.cell.2016.12.022","volume":"168","author":"MH Spitzer","year":"2017","unstructured":"Spitzer MH, Carmi Y, Reticker-Flynn NE, Kwek SS, Madhireddy D, Martins MM et al (2017) Systemic immunity is required for effective cancer immunotherapy. Cell 168(3):487\u2013502.e15","journal-title":"Cell"},{"issue":"4","key":"2359_CR13","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 22 mars 12(4):252\u2013264","journal-title":"Nat Rev Cancer 22 mars"},{"issue":"13","key":"2359_CR14","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1084\/jem.20090847","volume":"206","author":"LM Francisco","year":"2009","unstructured":"Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK et al (2009) PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 206(13):3015\u20133029","journal-title":"J Exp Med"},{"issue":"40","key":"2359_CR15","doi-asserted-by":"publisher","first-page":"66849","DOI":"10.18632\/oncotarget.19913","volume":"8","author":"R Pichler","year":"2017","unstructured":"Pichler R, Heidegger I, Fritz J, Danzl M, Sprung S, Zelger B et al (2017) PD-L1 expression in bladder cancer and metastasis and its influence on oncologic outcome after cystectomy. Oncotarget 8(40):66849\u201366864","journal-title":"Oncotarget"},{"issue":"1","key":"2359_CR16","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/ni.1674","volume":"10","author":"X Yu","year":"2009","unstructured":"Yu X, Harden K, Gonzalez LC, Francesco M, Chiang E, Irving B et al (2009) The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol 10(1):48\u201357","journal-title":"Nat Immunol"},{"issue":"42","key":"2359_CR17","doi-asserted-by":"publisher","first-page":"17858","DOI":"10.1073\/pnas.0903474106","volume":"106","author":"N Stanietsky","year":"2009","unstructured":"Stanietsky N, Simic H, Arapovic J, Toporik A, Levy O, Novik A et al (2009) The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci USA 106(42):17858\u201317863","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"2359_CR18","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","volume":"26","author":"RJ Johnston","year":"2014","unstructured":"Johnston RJ, Comps-Agrar L, Hackney J, Yu X, Huseni M, Yang Y et al (2014) The immunoreceptor TIGIT regulates antitumor and antiviral CD8+ T cell effector function. Cancer Cell 26(6):923\u2013937","journal-title":"Cancer Cell"},{"issue":"10","key":"2359_CR19","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1084\/jem.20100637","volume":"207","author":"J Fourcade","year":"2010","unstructured":"Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C et al (2010) Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 207(10):2175\u20132186","journal-title":"J Exp Med"},{"issue":"4","key":"2359_CR20","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s00345-015-1656-7","volume":"34","author":"C Cai","year":"2016","unstructured":"Cai C, Xu Y-F, Wu Z-J, Dong Q, Li M-Y, Olson JC et al (2016) Tim-3 expression represents dysfunctional tumor infiltrating T cells in renal cell carcinoma. World J Urol 34(4):561\u2013567","journal-title":"World J Urol"},{"issue":"6","key":"2359_CR21","doi-asserted-by":"publisher","first-page":"3810","DOI":"10.3892\/mmr.2017.6482","volume":"15","author":"Y Wang","year":"2017","unstructured":"Wang Y, Sun J, Gao W, Song B, Shao Q, Zhao L et al (2017) Preoperative Tim-3 expression on peripheral NK cells is correlated with pathologic TNM staging in colorectal cancer. Mol Med Rep 15(6):3810\u20133818","journal-title":"Mol Med Rep"},{"issue":"5","key":"2359_CR22","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1158\/2326-6066.CIR-16-0333","volume":"5","author":"H-B Jie","year":"2017","unstructured":"Jie H-B, Srivastava RM, Argiris A, Bauman JE, Kane LP, Ferris RL (2017) Increased PD-1\u2009+\u2009and TIM-3\u2009+\u2009TILs during cetuximab therapy inversely correlate with response in head and neck cancer patients. Cancer Immunol Res 5(5):408\u2013416","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"2359_CR23","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1158\/2326-6066.CIR-13-0171","volume":"2","author":"IP da Silva","year":"2014","unstructured":"da Silva IP, Gallois A, Jimenez-Baranda S, Khan S, Anderson AC, Kuchroo VK et al (2014) Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade. Cancer Immunol Res 2(5):410\u2013422","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"2359_CR24","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.intimp.2015.09.017","volume":"29","author":"L Xu","year":"2015","unstructured":"Xu L, Huang Y, Tan L, Yu W, Chen D, Lu C et al (2015) Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma. Int Immunopharmacol 29(2):635\u2013641","journal-title":"Int Immunopharmacol"},{"key":"2359_CR25","doi-asserted-by":"publisher","first-page":"232609","DOI":"10.1155\/2012\/232609","volume":"2012","author":"L Lima","year":"2012","unstructured":"Lima L, Dinis-Ribeiro M, Longatto-Filho A, Santos L (2012) Predictive biomarkers of bacillus calmette-gu\u00e9rin immunotherapy response in bladder cancer: where are we now? Adv Urol 2012:232609","journal-title":"Adv Urol"},{"issue":"2","key":"2359_CR26","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/S0022-5347(17)45605-9","volume":"135","author":"DR Kelley","year":"1986","unstructured":"Kelley DR, Haaff EO, Becich M, Lage J, Bauer WC, Dresner SM et al (1986) Prognostic value of purified protein derivative skin test and granuloma formation in patients treated with intravesical bacillus Calmette-Guerin. J Urol 135(2):268\u2013271","journal-title":"J Urol"},{"issue":"1","key":"2359_CR27","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1046\/j.1365-2249.1999.00756.x","volume":"115","author":"K Taniguchi","year":"1999","unstructured":"Taniguchi K, Koga S, Nishikido M, Yamashita S, Sakuragi T, Kanetake H et al (1999) Systemic immune response after intravesical instillation of bacille Calmette-Gu\u00e9rin (BCG) for superficial bladder cancer. Clin Exp Immunol 115(1):131\u2013135","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"2359_CR28","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.juro.2006.11.090","volume":"177","author":"GV Raj","year":"2007","unstructured":"Raj GV, Herr H, Serio AM, Donat SM, Bochner BH, Vickers AJ et al (2007) Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J Urol 177(4):1283\u20131286 (discussion 1286)","journal-title":"J Urol"},{"issue":"19","key":"2359_CR29","doi-asserted-by":"publisher","first-page":"4993","DOI":"10.1073\/pnas.1705327114","volume":"114","author":"AO Kamphorst","year":"2017","unstructured":"Kamphorst AO, Pillai RN, Yang S, Nasti TH, Akondy RS, Wieland A et al (2017) Proliferation of PD-1 + CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. Proc Natl Acad Sci USA 114(19):4993\u20134998","journal-title":"Proc Natl Acad Sci USA"},{"key":"2359_CR30","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.juro.2017.10.041","volume":"199","author":"AO Siefker-Radtke","year":"2018","unstructured":"Siefker-Radtke AO, Apolo AB, Bivalacqua TJ, Spiess PE, Black PC (2018) Immunotherapy with checkpoint blockade in the treatment of urothelial carcinoma. J Urol 199:1129\u20131142. \n                    https:\/\/doi.org\/10.1016\/j.juro.2017.10.041","journal-title":"J Urol."}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00345-018-2359-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-018-2359-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-018-2359-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T12:22:54Z","timestamp":1589631774000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00345-018-2359-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,2]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["2359"],"URL":"https:\/\/doi.org\/10.1007\/s00345-018-2359-7","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,2]]},"assertion":[{"value":"2 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical Standards"}},{"value":"NB is supported by the Parker Institute for Cancer Immunotherapy. AMF is supported by an NIH Immunology Training Grant (T32AI007605).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}